Methacycline

Summary

Methacycline (CHEMBL249837) is an approved small-molecule antibacterial drug (ATC J01AA05); indicated across 2 conditions including bacterial infectious disease and osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01AA05
• Indications: 2 conditions
• Chemistry: 442.4 Da · C22H22N2O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL249837
Name	Methacycline
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	54675785
ChEBI	CHEBI:6805
ATC	J01AA05
Molecular formula	C22H22N2O8
Molecular weight	442.4
InChIKey	XIYOPDCBBDCGOE-IWVLMIASSA-N

SMILES: CN(C)[C@H]1[C@@H]2[C@H]([C@@H]3C(=C)C4=C(C(=CC=C4)O)C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O

IUPAC name: (4S,4aR,5S,5aR,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide

ChEBI definition: A tetracycline that is the 6-methylene analogue of oxytetracycline, obtained by formal dehydration at position 6.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: GS-2876, Metaciclina, Metacycline, Methacycline, Motc, methacycline, METHACYCLINE, METACYCLINE, METHACYCLINE HYDROCHLORIDE, metacycline

Parent form; salt/anhydrous children: CHEMBL2146123

Patent coverage: 3,698 distinct patent families (13,102 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 13,045 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: NAD-dependent protein deacylase sirtuin-5, mitochondrial, Melanocortin receptor 4, Nuclear receptor subfamily 1 group I member 2, Multidrug transporter MdfA.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P0AEY8	5.6	IC50	2500	nM	CHEMBL_ACT_81343
SIRT5	5.44	IC50	3600	nM	CHEMBL_ACT_22986897
NR1I2	5.1	AC50	7900	nM	CHEMBL_ACT_25187883

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).